Evidence map›Paper›PMID 40265045›Full record

ArticleAutophagy reports2025

High throughput screening assay for the identification of ATF4 and TFEB activating compounds.

Daniel J Pfau, Ruslana Bryk

Abstract read
In one paragraph

Article in Autophagy reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel J PfauDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10065, United States.
Ruslana BrykDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10065, United States.

Funding

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activationR01AI138940 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI NATHAN, CARL FRANCIS · 2018 to 2022
$3.5M
NIAID NIH HHS R01 AI138940
6 · The paper itself

Abstract

Macrophages act to defend against infection, but can fail to completely prevent bacterial replication and dissemination in an immunocompetent host. Recent studies have shown that activation of a host transcription factor, TFEB, a regulator of lysosomal biogenesis, could restrict intramacrophage replication of the human pathogen

Indexed as

host-directed therapymacrophagemycobacteriastress responsetuberculosis

Identifiers

PMID40265045
PMCPMC11980509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.